The global pulmonary drug delivery systems market size is expected to reach around US$ 92.4 billion by 2030 from US$ 51.87 billion in 2021 and is expected to grow at an impressive double-digit rate of 6.6% from 2021 to 2030.
The study includes drivers and restraints of this market. The study provides an analysis of the global pulmonary drug delivery systems market for the period 2017-2030, wherein 2021 to 2030 is the forecast period and 2020 is considered as the base year.
Pulmonary drug delivery system is a targeted drug delivery in which a part of the drug is directed towards the targeted site or the respiratory tract. Simply, the pulmonary drug delivery systems is a device used for administration of drugs through the pulmonary route for the treatment of various respiratory diseases. The rising prevalence of respiratory diseases such as chronic obstructive pulmonary disease, asthma, and cystic fibrosis is the primary reason behind the burgeoning demand for the pulmonary drug delivery systems across the globe. According to the World Health Organization, COPD caused around 3.23 million deaths in 2019 and it was the third leading cause of death across the globe. Moreover, around 262 million people across the globe were affected with asthma in 2019, and it caused 461,000 deaths in the same year.
We customize your report according to your research need. REQUEST CUSTOMIZED COPY OF REPORT (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/customization/1502
Why should you invest in this report?
If you are aiming to enter the global pulmonary drug delivery systems market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for pulmonary drug delivery systems are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030, so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Some of the prominent players in the global pulmonary drug delivery systems market include:
- Philips Respironics
- GlaxoSmithKline PLC
- BoehringerIngelheim GmbH
- TevaPharmaceutical Industries Ltd.
- 3M Healthcare
- PARI GmbH
- F. Hoffmann-La Roche AG
- Gilbert Technologies
- AstraZeneca PLC
- Omron Healthcare, Inc.
Market Segmentation:
By Product
- Dry Powder Inhalers
- Nebulizers
- Metered Dose Inhalers
- Accessories
By Indication
- COPD
- Asthma
- Cystic Fibrosis
- Allergic Rhinitis
- Others
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- E-Commerce
Regional Analysis:
The geographical analysis of the global pulmonary drug delivery systems market has been done for North America, Europe, Asia-Pacific, and the Rest of the World.
The North American Market is again segmented into the US, Canada, and Mexico. Coming to the European Market, it can be segmented further into the UK, Germany, France, Italy, Spain, and the rest. Coming to the Asia-Pacific, the global pulmonary drug delivery systems Market is segmented into China, India, Japan, and Rest of Asia Pacific. Among others, the market is segmented into the Middle East and Africa, (GCC, North Africa, South Africa and Rest of the Middle East & Africa).
Key Questions Answered by the Report:
- What will be the size of the global pulmonary drug delivery systems market in 2030?
- What is the expected CAGR for the pulmonary drug delivery systems market between 2021 and 2030?
- Which are the top players active in this global market?
- What are the key drivers of this global market?
- How will the market situation change in the coming years?
- Which region held the highest market share in this global market?
- What are the common business tactics adopted by players?
- What is the growth outlook of the global pulmonary drug delivery systems market?
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Pulmonary Drug Delivery Systems Market
5.1. COVID-19 Landscape: Pulmonary Drug Delivery Systems Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Pulmonary Drug Delivery Systems Market, By Product
8.1. Pulmonary Drug Delivery Systems Market, by Product Type, 2021-2030
8.1.1. Dry Powder Inhalers
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Nebulizers
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Metered Dose Inhalers
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Accessories
8.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Pulmonary Drug Delivery Systems Market, By Indication
9.1. Pulmonary Drug Delivery Systems Market, by Indication, 2021-2030
9.1.1. COPD
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Asthma
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Cystic Fibrosis
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Allergic Rhinitis
9.1.4.1. Market Revenue and Forecast (2019-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Pulmonary Drug Delivery Systems Market, By Distribution Channel
10.1. Pulmonary Drug Delivery Systems Market, by Distribution Channel, 2021-2030
10.1.1. Retail Pharmacy
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Hospital Pharmacy
10.1.2.1. Market Revenue and Forecast (2019-2030)
10.1.3. E-Commerce
10.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Pulmonary Drug Delivery Systems Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2019-2030)
11.1.2. Market Revenue and Forecast, by Indication (2019-2030)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.1.4.2. Market Revenue and Forecast, by Indication (2019-2030)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.1.5.2. Market Revenue and Forecast, by Indication (2019-2030)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.2. Market Revenue and Forecast, by Indication (2019-2030)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.4.2. Market Revenue and Forecast, by Indication (2019-2030)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.5.2. Market Revenue and Forecast, by Indication (2019-2030)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.6.2. Market Revenue and Forecast, by Indication (2019-2030)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.7.2. Market Revenue and Forecast, by Indication (2019-2030)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.2. Market Revenue and Forecast, by Indication (2019-2030)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.4.2. Market Revenue and Forecast, by Indication (2019-2030)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.5.2. Market Revenue and Forecast, by Indication (2019-2030)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.6.2. Market Revenue and Forecast, by Indication (2019-2030)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.7.2. Market Revenue and Forecast, by Indication (2019-2030)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.2. Market Revenue and Forecast, by Indication (2019-2030)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.4.2. Market Revenue and Forecast, by Indication (2019-2030)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.5.2. Market Revenue and Forecast, by Indication (2019-2030)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.6.2. Market Revenue and Forecast, by Indication (2019-2030)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.7.2. Market Revenue and Forecast, by Indication (2019-2030)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.5.2. Market Revenue and Forecast, by Indication (2019-2030)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.5.4.2. Market Revenue and Forecast, by Indication (2019-2030)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.5.5.2. Market Revenue and Forecast, by Indication (2019-2030)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
Chapter 12. Company Profiles
12.1. Philips Respironics
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. GlaxoSmithKline PLC
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. BoehringerIngelheim GmbH
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. TevaPharmaceutical Industries Ltd.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. 3M Healthcare
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. PARI GmbH
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. F. Hoffmann-La Roche AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Gilbert Technologies
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. AstraZeneca PLC
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Omron Healthcare, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1502
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
0 Comments